Location Directory

Clinical trials in Atlanta, Georgia

This page shows live ClinicalTrials.gov search results for Atlanta, Georgia, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

13063

Shown on this page

Current sort

Institutions in Atlanta

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Emory University (Winship Cancer Institute)

Live official records

Open in full search

Conditions: Ulcerative Colitis (UC)
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 8,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 170
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 133 more

Conditions: Crohn's Disease
Interventions: TAK-279, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 30
States / cities: Murrieta, California • Orange, California • Clearwater, Florida + 27 more

Conditions: Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IIIC1 Cervical Cancer FIGO 2018, Stage IIIC2 Cervical Cancer FIGO 2018, Stage IVA Cervical Cancer FIGO 2018
Interventions: Biospecimen Collection, Brachytherapy, Carboplatin, Chest Radiography, Cisplatin, Computed Tomography, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Positron Emission Tomography; Procedure · Radiation · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 344
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 265 more

Conditions: Aortic Valve Stenosis
Interventions: Medtronic Transcatheter Aortic Valve Replacement Systems, Surgical Aortic Valve Replacement (SAVR); Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: Not listed
Enrollment: 2,223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 61
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 53 more

Conditions: Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Interventions: Casdatifan, Cabozantinib, Placebo; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 46
States / cities: Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 40 more

Conditions: Clear Cell Renal Cell Carcinoma, Solid Tumors
Interventions: casdatifan, Cabozantinib, Zimberelimab, Ipilimumab; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 20
States / cities: Birmingham, Alabama • San Diego, California • Santa Monica, California + 13 more

Conditions: Systemic Lupus Erythematosus (SLE)
Interventions: Current standard of care treatment options; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 16 Years and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 26
States / cities: La Jolla, California • La Palma, California • Los Angeles, California + 22 more

Conditions: Low Grade Serous Ovarian Cancer
Interventions: avutometinib, Defactinib, Pegylated liposomal doxorubicin, Paclitaxel, Letrozole, Anastrozole; Drug
Lead sponsor: Verastem, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 38
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more

Conditions: Metastatic Breast Cancer
Interventions: Palbociclib 125mg, Ribociclib 600mg, Ribociclib, Palbociclib; Drug
Lead sponsor: American Society of Clinical Oncology; Other
Eligibility: 60 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 92
States / cities: Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 79 more

Conditions: Neoplasms
Interventions: Gene-modified (GM) T cell therapy; Genetic
Lead sponsor: Celgene; Industry
Eligibility: Not listed
Enrollment: 1,541 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2043
U.S. locations: 104
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 75 more

Conditions: Major Depressive Disorder
Interventions: NBI-1065845; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 49
States / cities: Huntsville, Alabama • Bryant, Arkansas • Little Rock, Arkansas + 42 more

Conditions: Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM), Glioma, Central Nervous System Diseases, Brain Cancer
Interventions: silevertinib in combination with temozolomide, temozolomide (TMZ); Drug
Lead sponsor: Black Diamond Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 38
States / cities: Birmingham, Alabama • Springdale, Arkansas • La Jolla, California + 33 more

Clinical trials in Atlanta, Georgia

Filter and sort this location

Institutions in Atlanta

Live official records

A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII